IP Library Granted Patent US 8,288,142
Granted Patent B2
US 8,288,142 · App. 12/664,667 · Granted Oct 16, 2012

Hyaluronidase and method of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,142
App. No.
12/664,667
Granted
Oct 16, 2012
Kind
B2
Abstract

The present invention provides a tnaluronidase. The hyaluronidase can be produced by the strain Streptomyces aitinocidm 77, Exemplary characteristics of the hyaluronidase include specific C-terminal or other amino acid sequences, including full-length sequences, and improved physico-chemical and actix itj properties as compared to known h> alυronidase preparatkiiis. Described are also various uses of the hyaiurυnidasc, including topical administration of the h> aiuronidasc to improve skin penetration of a co-administered active substance.

Claims (6)

1. An isolated hyaluronidase protein comprising an amino acid sequence as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:4.

2. The isolated hyaluronidase protein of claim 1 , comprising the amino acid sequence of at least one of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:4.

3. The isolated sequence of claim 1 , comprising a full-length hyaluronidase from S. actinocidus 77.

4. A pharmaceutical formulation comprising the isolated hyaluronidase of claim 1 and a pharmaceutically acceptable excipient, carrier, diluent, or auxiliary agent.

5. The pharmaceutical formulation of claim 4 , wherein the excipient is mannitol.

6. A transdermal delivery article comprising the pharmaceutical formulation of claim 4 .

Continuity (2)
Provisional Application 60945037 · Jun 19, 2007
Related Publication 20100172892A1 · Jul 8, 2010